Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane

References

• Cancer Research UKCancerStats: Cancer Worldwide Available from: http://info.cancerresearchuk.org/cancerstats/world/commoncancers/index.htmAccessed 2010 Jan 10
   Google Scholar
• BeatsonGTOn treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative casesLancet18962162165
   Google Scholar
• SantenRJBrodieHSimpsonERSiiteriPKBrodieAHistory of aromatase: saga of an important biological mediator and therapeutic targetEndocr Rev200930434337519389994
   PubMed Web of Science ®Google Scholar
• JordanVCTamoxifen: a most unlikely pioneering medicineNat Rev Drug Discov20032320521312612646
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• MillerWRAromatase inhibitors: mechanism of action and role in the treatment of breast cancerSemin Oncol2003304 Suppl 1431114513432
   PubMed Web of Science ®Google Scholar
• GeislerJKingNAnkerGIn vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patientsClin Cancer Res199849208920939748124
   PubMed Web of Science ®Google Scholar
• GeislerJHaynesBAnkerGDowsettMLonningPEInfluence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over studyJ Clin Oncol200220375175711821457
   PubMed Web of Science ®Google Scholar
• NabholtzJMBonneterreJBuzdarARobertsonJFThurlimannBAnastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsEur J Cancer200339121684168912888362
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol200321112101210912775735
   PubMed Web of Science ®Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551
   PubMed Web of Science ®Google Scholar
• EvansTRDi SalleEOrnatiGPhase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal womenCancer Res19925221593359391394219
   PubMed Web of Science ®Google Scholar
• JohannessenDCEnganTDi SalleEEndocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I studyClin Cancer Res199737110111089815789
   PubMed Web of Science ®Google Scholar
• LonningPPfisterCMartoniAZamagniCPharmacokinetics of third-generation aromatase inhibitorsSemin Oncol2003304 Suppl 14233214513434
   PubMed Web of Science ®Google Scholar
• Pharmacia LtdExemestane – Summary of product characteristics Available from: http://emc.medicines.org.uk/medicine/2484/SPC/Aromasin/Accessed 2010 Mar 16
   Google Scholar
• JonesSVogelCArkhipovAMulticenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study GroupJ Clin Oncol199917113418342510550136
   PubMed Web of Science ®Google Scholar
• LonningPEBajettaEMurrayRActivity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trialJ Clin Oncol200018112234224410829043
   PubMed Web of Science ®Google Scholar
• KvinnslandSAnkerGDirixLYHigh activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatmentEur J Cancer200036897698210885600
   PubMed Web of Science ®Google Scholar
• KaufmannMBajettaEDirixLYExemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized doubleblind trial. The Exemestane Study GroupJ Clin Oncol20001871399141110735887
   PubMed Web of Science ®Google Scholar
• ParidaensRDirixLLohrischCMature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerAnn Oncol20031491391139812954578
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trialLancet2007369956155957017307102
   PubMed Web of Science ®Google Scholar
• CoombesRKilburnLBeareSSnowdonCBlissJSurvival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) – submitted on behalf of the IES InvestigatorsEur J Cancer Supps200972263
   Web of Science ®Google Scholar
• JonesSESeynaeveCHasenburgAResults of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancerCancer Res200969Suppl 2 Abstract 15
   Web of Science ®Google Scholar
• ReaDHasenburgASeynaeveCFive years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM Trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancerCancer Res200969Suppl 24 Abstract 11
   Web of Science ®Google Scholar
• MouridsenHGiobbie-HurderAGoldhirschALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med2009361876677619692688
   PubMed Web of Science ®Google Scholar
• MamounasEPJeongJHWickerhamDLBenefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trialJ Clin Oncol200826121965197118332472
   PubMed Web of Science ®Google Scholar
• Phase III randomized adjuvant study of exemestane versus anastrozole in postmenopausal women with receptor-positive primary breast cancer (CAN-NCIC-MA27) Available from: http://www.cancer.gov/clinicaltrials/ft-CAN-NCIC-MA27Accessed 2010 Mar 16
   Google Scholar
• ChlebowskiRTGellerMLAdherence to endocrine therapy for breast cancerOncology2006711–21917344666
   PubMed Web of Science ®Google Scholar
• PartridgeAHLaFountainAMayerETaylorBSWinerEAsnis-AlibozekAAdherence to initial adjuvant anastrozole therapy among women with early-stage breast cancerJ Clin Oncol200826455656218180462
   PubMed Web of Science ®Google Scholar
• JonesSECantrellJVukeljaSComparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyJ Clin Oncol200725304765477117947724
   PubMed Web of Science ®Google Scholar
• FallowfieldLCellaDCuzickJFrancisSLockerGHowellAQuality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer TrialJ Clin Oncol200422214261427115514369
   PubMed Web of Science ®Google Scholar
• ThurlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• ThomasRWilliamsMMarshallCWalkerLSwitching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant womenBr J Cancer20089891494149918392053
   PubMed Web of Science ®Google Scholar
• FallowfieldLJBlissJMPorterLSQuality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerJ Clin Oncol200624691091716484701
   PubMed Web of Science ®Google Scholar
• HickeyMSaundersCPartridgeASantoroNJoffeHStearnsVPractical clinical guidelines for assessing and managing menopausal symptoms after breast cancerAnn Oncol200819101669168018522932
   PubMed Web of Science ®Google Scholar
• MouridsenHTIncidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal womenCurr Med Res Opin20062281609162116870085
   PubMed Web of Science ®Google Scholar
• BuzdarAHowellACuzickJComprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trialLancet Oncol20067863364316887480
   PubMed Web of Science ®Google Scholar
• MoralesLPansSParidaensRDebilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imagingBreast Cancer Res Treat20071041879117061044
   PubMed Web of Science ®Google Scholar
• HenryNLGilesJTStearnsVAromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementOncology (Williston Park)200822121401140819086600
   PubMed Web of Science ®Google Scholar
• RogersASalehGHannonRAGreenfieldDEastellRCirculating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal womenJ Clin Endocrinol Metab200287104470447512364420
   PubMed Web of Science ®Google Scholar
• CummingsSRBrownerWSBauerDEndogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research GroupN Engl J Med1998339117337389731089
   PubMed Web of Science ®Google Scholar
• ChapurlatRDGarneroPBreartGMeunierPJDelmasPDSerum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS studyJ Bone Miner Res20001591835184110977003
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJATidyAAshleySEffect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol199614178848558225
   PubMed Web of Science ®Google Scholar
• LoveRRMazessRBBardenHSEffects of tamoxifen on bone mineral density in postmenopausal women with breast cancerN Engl J Med1992326138528561542321
   PubMed Web of Science ®Google Scholar
• ReschABiberESeifertMReschHEvidence that tamoxifen preserves bone density in late postmenopausal women with breast cancerActa Oncol1998377–866166410050983
   PubMed Web of Science ®Google Scholar
• KristensenBEjlertsenBDalgaardPTamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized studyJ Clin Oncol19941259929978164053
   PubMed Web of Science ®Google Scholar
• GreyABStapletonJPEvansMCTatnellMAAmesRWReidIRThe effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal womenAm J Med19959966366417503087
   PubMed Web of Science ®Google Scholar
• ColemanREBanksLMGirgisSISkeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled studyLancet Oncol20078211912717267326
   PubMed Web of Science ®Google Scholar
• GonnelliSCadirniACaffarelliCChanges in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestaneBone200740120521016904960
   PubMed Web of Science ®Google Scholar
• HadjiPZillerMKiebackDGEffects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomized substudyAnn Oncol20092071203120919218306
   PubMed Web of Science ®Google Scholar
• JonesSStokoeCSborovMThe effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancerClin Breast Cancer20088652753219073509
   PubMed Web of Science ®Google Scholar
• GeislerJLonningPEKragLEChanges in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized, placebo-controlled studyEur J Cancer200642172968297516963261
   PubMed Web of Science ®Google Scholar
• GossPEQiSCheungAMHuHMendesMPritzkerKPEffects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized ratsClin Cancer Res200410175717572315355898
   PubMed Web of Science ®Google Scholar
• GossPEHadjiPSubarMAbreuPThomsenTBanke-BochitaJEffects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal womenBreast Cancer Res200794R5217692126
   PubMed Web of Science ®Google Scholar
• McCloskeyEVHannonRALaknerGEffects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomized, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenEur J Cancer200743172523253118029171
   PubMed Web of Science ®Google Scholar
• McCloskeyEEffects of third-generation aromatase inhibitors on boneEur J Cancer20064281044105116554149
   PubMed Web of Science ®Google Scholar
• HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol200321214042405712963702
   PubMed Web of Science ®Google Scholar
• ReidDMDoughtyJEastellRGuidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert GroupCancer Treat Rev200834Suppl 1S3S1818515009
   PubMed Web of Science ®Google Scholar
• EwerMSGluckSA woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular healthCancer200911591813182619235248
   PubMed Web of Science ®Google Scholar
• KannelWBMetabolic risk factors for coronary heart disease in women: perspective from the Framingham StudyAm Heart J198711424134193604900
   PubMed Web of Science ®Google Scholar
• BassKMNewschafferCJKlagMJBushTLPlasma lipoprotein levels as predictors of cardiovascular death in womenArch Intern Med199315319220922168215724
   PubMedGoogle Scholar
• MarkopoulosCPolychronisADafniULipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudyAnn Oncol2009201495518678766
   PubMed Web of Science ®Google Scholar
• FranciniGPetrioliRMontagnaniAExemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipidsBr J Cancer200695215315816835585
   PubMed Web of Science ®Google Scholar
• MarkopoulosCDafniUMisitzisJExtended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudyBreast Cancer Res2009113R3519531217
   PubMed Web of Science ®Google Scholar
• GreyABStapletonJPEvansMCReidIRThe effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal womenJ Clin Endocrinol Metab19958011319131957593425
   PubMed Web of Science ®Google Scholar
• MouridsenHKeshaviahACoatesASCardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1–98 trialJ Clin Oncol200725365715572217998546
   PubMed Web of Science ®Google Scholar
• CupponeFBriaEVermaSDo adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsCancer2008112226026718041059
   PubMed Web of Science ®Google Scholar
• BertelliGHallEIrelandELong-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) – a randomized controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifenAnn Oncol201021349850519717534
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJWaleCHowellTHoughtonJBaumMRetrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyJ Clin Oncol200523307512751716234518
   PubMed Web of Science ®Google Scholar
• BartlettJBrookesCBillinghamLA prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifenCancer Res200969Suppl 2 Abstract 81
   Web of Science ®Google Scholar
• VialeGReganMMMaioranoEPrognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98J Clin Oncol200725253846385217679725
   PubMed Web of Science ®Google Scholar
• DowsettMAllredCKnoxJRelationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialJ Clin Oncol20082671059106518227529
   PubMed Web of Science ®Google Scholar
• BartlettJBrookesCRobsonTThe TEAM trial pathology study identifies potential prognostic and predictive biomarker models for postmenopausal patients treated with endocrine therapyCancer Res200969Suppl 24 Abstract 75
   Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• WalsheJMDenduluriNSwainSMAmenorrhea in premenopausal women after adjuvant chemotherapy for breast cancerJ Clin Oncol200624365769577917130515
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMYapYSAdjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhea: caution and suggested guidelinesJ Clin Oncol200624162444244716735701
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdfAccessed 2010 Mar 23
   Google Scholar